Scientists watch cancer drugs at work

Cancer Research UK

A sophisticated scanning technique has allowed researchers to watch in real time as anti-cancer drugs attack a patient's tumour, a new study reveals1.

Cancer Research UK scientists in London, Newcastle and Manchester used the technique to track a drug within tumours and make accurate assessments of its effectiveness.

The system should enable doctors to spot early signs that treatment is failing to work, allowing a speedy switch to an alternative drug. It may also dramatically speed up clinical trials, by making it far easier for researchers to collect information on a drug's function.

It is very difficult for doctors to assess whether a cancer treatment is succeeding without undertaking an invasive biopsy. But researchers based at the MRC Cyclotron Unit in London's Hammersmith Hospital and the Northern Institute for Cancer Research in Newcastle used a high tech, non-invasive imaging technique called Positron Emission Tomography (PET) to track the effectiveness of treatment.

Scientists studied patients who were being treated at Newcastle General Hospital for bowel or stomach cancer, flying them down to the Hammersmith for their PET scans. The patients were receiving a drug called nolatrexed (or Thimitaq), which stops cancer cells from making thymidine - a key component of DNA that's vital for cell division. By injecting them with mildly radioactive molecules of thymidine, researchers were able to watch on screen as the anti-cancer drug took effect.

Cancer Research UK's Professor Pat Price has recently moved from the Hammersmith to the Christie Hospital in Manchester, where she is helping to found the new multimillion pound Wolfson Molecular Imaging Centre. She says: "When a drug prevents tumours from making the molecules they need for their growth, they have to frantically smuggle them in from outside instead, and we can visualise this with the new scanning technique to build up a picture of exactly how well the treatment is working."

Cancer cells only draw in thymidine from outside if a drug is preventing them from making it, so such an action is a marker of the effectiveness of treatment. But if cancer cells are able to smuggle in very large quantities of thymidine, it may give them resistance to the drug's effects, and once perfected, the new system should be able to detect this as well.

Prof Price adds: "It should allow us to make much earlier decisions about whether or not a drug is working, opening the way to a far more flexible approach to treating patients, with doctors able to turn from one drug to the next as necessary.

Fellow Cancer Research UK scientist Professor Herbie Newell, from the Northern Institute for Cancer Research, says: "This system will not only be extremely useful for monitoring an individual's treatment, but may also allow us to reduce the time is takes to put drugs through clinical trials, because it will become apparent much earlier in a study whether or not a drug is likely to be effective."

Professor Robert Souhami, Cancer Research UK's Director of Clinical Research, says: "For the first time we have a technique which allows us to measure directly within a tumour whether a drug is working, without the need for a biopsy.

"This technique will greatly assist the assessment of new anti-cancer drugs and allow them to get into clinical practice more quickly."

ENDS

  1. Journal of the National Cancer Institute95 (9) (May 7, 2003)

Note to editors:

The study also received funding from America's National Cancer Institute.